血浆胱抑素C作为接受多替拉韦方案治疗的HIV-1感染者估算肾小球滤过率的标志物
研究纳入44例HIV-1感染者,在启动多替拉韦前后检测冻存血浆肌酐与胱抑素C,用CKD-EPI方程估算GFR。启动多替拉韦后血肌酐显著升高、肌酐估算GFR显著下降,而胱抑素C值及其估算GFR无显著变化。
要点
- 启动多替拉韦后血肌酐升高+8.6 μmol/L(95% CI +5.8; +11.4,P < 0.001),肌酐估算GFR下降-7.7 mL/min/1.73 m2(95% CI -10.4; -5.1,P < 0.001)。
- 胱抑素C值变化及其估算GFR在启动多替拉韦前后无显著变化。
- 无论基线肾功能如何,结果一致。
核心结论
- 启动多替拉韦后血肌酐升高,而胱抑素C值无变化;使用胱抑素C可能有助于更好理解启动多替拉韦后血浆肌酐波动,尤其在高肾脏风险患者中。
研究设计与样本
- 研究对2016年10月至2017年3月期间在Pitié-Salpêtrière医院收集的HIV-1感染者冻存血浆样本,在启动多替拉韦前后进行肌酐和胱抑素C检测,采用CKD-EPI方程估算平均GFR,用配对t检验分析变化。
- 共纳入44例患者,中位年龄48岁(IQR 36-58),中位CD4计数592 cells/mm3(IQR 388-728),其中6例为ART初治,38例为转换策略(72%病毒载量<50 copies/mL,中位ART疗程13年(IQR 5-20))。
主要发现
- 启动多替拉韦前(中位时间41天),19例(43%)肌酐估算GFR<90 mL/min/1.73 m2,11例(25%)胱抑素C估算GFR<90 mL/min/1.73 m2。
- 启动多替拉韦后,血肌酐显著升高+8.6 μmol/L(95% CI +5.8; +11.4,P < 0.001),肌酐估算GFR显著下降-7.7 mL/min/1.73 m2(95% CI -10.4; -5.1,P < 0.001)。
- 胱抑素C值变化及其估算GFR无显著变化。
- 无论基线肾功能如何,观察到相同结果。
临床怎么用
- 作者认为,使用胱抑素C可能有助于更好理解启动多替拉韦后血浆肌酐波动,尤其在高肾脏风险患者中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Inhibition of the organic cation transporter-2 renal tubule transporter by dolutegravir leads to serum creatinine increase. Serum cystatin C is a non-organic cation transporter-2-dependent marker, possibly enabling glomerular filtration rate (GFR) estimation under dolutegravir. Our goal was to evaluate the changes in creatinine- and cystatin C-based estimated GFR values before and after dolutegravir initiation. METHODS: Creatinine and cystatin measurements were carried out on frozen plasma samples from HIV-1-infected patients, before and after dolutegravir initiation, between October 2016 and March 2017 at Pitié-Salpêtrière Hospital. CKD-EPI equations were used to estimate mean GFR from creatinine and cystatin C values. Variations were analysed by paired t-test. RESULTS: Forty-four patients were included [median age = 48 years (IQR 36-58) and median CD4 count = 592 cells/mm3 (IQR 388-728)], including 6 ART-naive patients and 38 on switch strategies [72% with viral load <50 copies/mL and median ART duration = 13 years (IQR 5-20)]. Before dolutegravir initiation (median time = 41 days), 19 patients (43%) had creatinine-based estimated GFR <90 mL/min/1.73 m2 and 11 (25%) had cystatin C-based estimated GFR <90 mL/min/1.73 m2. After dolutegravir initiation, serum creatinine values significantly increased (+8.6 μmol/L, 95% CI +5.8; +11.4, P < 0.001) and associated estimated GFR significantly decreased (-7.7 mL/min/1.73 m2, 95% CI -10.4; -5.1, P < 0.001). In contrast, there was no significant change in cystatin C value variation and associated estimated GFR. The same results were observed regardless of renal function at baseline. CONCLUSIONS: Creatinine values increased after dolutegravir initiation, whereas no change was observed for cystatin C values. Use of cystatin C may enable better understanding of plasma creatinine fluctuations after dolutegravir initiation, particularly in high-risk renal patients.
引用
- Palich R, Tubiana R, Abdi B, et al. Plasma cystatin C as a marker for estimated glomerular filtration rate assessment in HIV-1-infected patients treated with dolutegravir-based ART. J Antimicrob Chemother. 2018. PMID: 29688533. doi:10.1093/jac/dky112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。